前礼来销售代表指控公司违规推广Mounjaro糖尿病药物
STAT+: Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug
前礼来销售代表Jennifer Mansion在德州联邦法院提起诉讼,指控公司未经批准即推广Mounjaro用于减肥。这种做法在制药行业被称为超说明书使用。
![]()
By Ed Silverman
Nov. 10, 2026
Pharmalot Columnist, Senior Writer
Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter.
A former Eli Lilly sales rep filed a lawsuit alleging that she was fired after complaining the company was promoting its Mounjaro diabetes drug to combat weight loss before receiving regulatory approval to do so.
Jennifer Mansion, who was hired as a senior territory manager in Dallas four years ago, claimed that she observed other Lilly sales reps promoting the diabetes drug as a salve for obesity. Mansion also contended that a physician touted Mounjaro as a weight-loss option during a luncheon sponsored by the drugmaker, according to the suit filed in federal court in Texas.
Such promotions are known as off-label marketing in the pharmaceutical industry. The phrase refers to promoting a medicine for a usage that was not approved by the U.S. Food and Drug Administration. A physician may prescribe a medicine for an unapproved use, but a drugmaker is not permitted to market its drug for that purpose.
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
来源:STAT Pharma 医药频道 · statnews.com